Advertisement

Ads Placeholder
Loading...

Idorsia Ltd

IDRSFPNK
Healthcare
Biotechnology
$4.38
$0.00(0.00%)
U.S. Market opens in 3h 30m

Idorsia Ltd Fundamental Analysis

Idorsia Ltd (IDRSF) shows weak financial fundamentals with a PE ratio of -7.65, profit margin of -50.91%, and ROE of 9.88%. The company generates $0.2B in annual revenue with weak year-over-year growth of -26.17%.

Key Strengths

PEG Ratio-0.43

Areas of Concern

ROE9.88%
Operating Margin-14.63%
We analyze IDRSF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -17.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-17.4/100

We analyze IDRSF's fundamental strength across five key dimensions:

Efficiency Score

Weak

IDRSF struggles to generate sufficient returns from assets.

ROA > 10%
-24.10%

Valuation Score

Excellent

IDRSF trades at attractive valuation levels.

PE < 25
-7.65
PEG Ratio < 2
-0.43

Growth Score

Moderate

IDRSF shows steady but slowing expansion.

Revenue Growth > 5%
-26.17%
EPS Growth > 10%
13.17%

Financial Health Score

Excellent

IDRSF maintains a strong and stable balance sheet.

Debt/Equity < 1
-1.11
Current Ratio > 1
1.39

Profitability Score

Weak

IDRSF struggles to sustain strong margins.

ROE > 15%
9.88%
Net Margin ≥ 15%
-50.91%
Positive Free Cash Flow
No

Key Financial Metrics

Is IDRSF Expensive or Cheap?

P/E Ratio

IDRSF trades at -7.65 times earnings. This suggests potential undervaluation.

-7.65

PEG Ratio

When adjusting for growth, IDRSF's PEG of -0.43 indicates potential undervaluation.

-0.43

Price to Book

The market values Idorsia Ltd at -0.76 times its book value. This may indicate undervaluation.

-0.76

EV/EBITDA

Enterprise value stands at 6.99 times EBITDA. This is generally considered low.

6.99

How Well Does IDRSF Make Money?

Net Profit Margin

For every $100 in sales, Idorsia Ltd keeps $-50.91 as profit after all expenses.

-50.91%

Operating Margin

Core operations generate -14.63 in profit for every $100 in revenue, before interest and taxes.

-14.63%

ROE

Management delivers $9.88 in profit for every $100 of shareholder equity.

9.88%

ROA

Idorsia Ltd generates $-24.10 in profit for every $100 in assets, demonstrating efficient asset deployment.

-24.10%

Following the Money - Real Cash Generation

Operating Cash Flow

Idorsia Ltd generates limited operating cash flow of $-160.39M, signaling weaker underlying cash strength.

$-160.39M

Free Cash Flow

Idorsia Ltd generates weak or negative free cash flow of $-173.36M, restricting financial flexibility.

$-173.36M

FCF Per Share

Each share generates $-0.70 in free cash annually.

$-0.70

FCF Yield

IDRSF converts -20.07% of its market value into free cash.

-20.07%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-7.65

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.43

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.76

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.91

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.11

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.39

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.10

vs 25 benchmark

ROA

Return on assets percentage

-0.24

vs 25 benchmark

ROCE

Return on capital employed

-0.11

vs 25 benchmark

How IDRSF Stacks Against Its Sector Peers

MetricIDRSF ValueSector AveragePerformance
P/E Ratio-7.6528.23 Better (Cheaper)
ROE9.88%737.00% Weak
Net Margin-50.91%-46175.00% (disorted) Weak
Debt/Equity-1.110.35 Strong (Low Leverage)
Current Ratio1.394.10 Neutral
ROA-24.10%-17785.00% (disorted) Weak

IDRSF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Idorsia Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

245.23%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

61.03%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

41.43%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ